storage stability is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A text known as The Ritual of Embalming does describe some of the practical logistics of embalming; however, there are only two known copies and each is incomplete. With regards to mummification shown in images, there are apparently also very few. The tomb of Tjay, designated TT23, is one of only two known which show the wrapping of a mummy (Riggs 2014). Another text that describes the processes being used in the latter periods is Herodotus' Histories. Written in Book 2 of the Histories is one of the most detailed descriptions of the Egyptian mummification process, including the mention of using natron in order to dehydrate corpses for preservation. However, these descriptions are short and fairly vague, leaving scholars to infer the majority of the techniques that were used by studying mummies that have been unearthed. By utilizing current advancements in technology, scientists have been able to uncover a plethora of new information about the techniques used in mummification. A series of CT scans performed on a 2,400-year-old mummy in 2008 revealed a tool that was left inside the cranial cavity of the skull. The tool was a rod, made of an organic material, that was used to break apart the brain to allow it to drain out of the nose. This discovery helped to dispel the claim within Herodotus' works that the rod had been a hook made of iron. Earlier experimentation in 1994 by researchers Bob Brier and Ronald Wade supported these findings.
=== Diagnostic imaging === The insulinoma might be localized by noninvasive means, using ultrasound, CT scan, or MRI techniques. An indium-111 pentetreotide scan is more sensitive than ultrasound, CT, or MRI for detection of somatostatin receptor positive tumours, but not a good diagnostic tool for insulinomas. An endoscopic ultrasound has a sensitivity of 40-93% (depending on the location of the tumour) for detecting insulinomas. Sometimes, angiography with percutaneous transhepatic pancreatic vein catheterization to sample the blood for insulin levels is required. Calcium can be injected into selected arteries to stimulate insulin release from various parts of the pancreas, which can be measured by sampling blood from their respective veins. The use of calcium stimulation improves the specificity of this test.During surgery to remove an insulinoma, an intraoperative ultrasound can sometimes localize the tumour, which helps guide the surgeon in the operation and has a higher sensitivity than noninvasive imaging tests.
== Museum history == The Arabia Steamboat Museum opened on November 13, 1991. Various elements of the museum operated under different corporations: Arabia Instructional Museum Society (1995-2004), Arabia Museum Foundation (founded 1990) and Arabia Salvage Ltd.(founded 1988). The museum and its operations were led by the two brothers who found and excavated the Arabia, Greg and David Hawley, and their parents, Bob and Florence Hawley. Greg was killed by a street racing driver in 2009. Bob died in 2019 and Florence died in 2021. David has continued the operation. The lease in Kansas City (7 miles from the Arabia wreck site) expires in 2026. Plans have been developed to move and expand the Arabia Steamboat Museum. In 2019, it was proposed to build the larger museum and move to Jefferson City, about 140 miles from the site of the Arabia wreck. In 2021, plans were made to create the National Steamboat Museum at Marshall Junction, Missouri, about 77 miles from the site of the wreck. The plans include excavating five additional steamboats so that six are interpreted and displayed at the museum. The Marshall-Saline Development Corporation advance funded a $150,000 feasibility study for the new museum, but is not raising or collecting funds for the museum. On November 13, 2025, the museum announced on their website that they would be closing permanently in November 2026.
=== Second generation === In 1976, 24-year-old Rich Snyder became the company president after his father's death. Along with his brother Guy, Rich had begun working in his father's In-N-Outs at an early age. Over the next 20 years, the chain experienced a period of rapid growth under Rich's leadership, expanding to 93 restaurants. In June 1988, In-N-Out opened its 50th location, in Thousand Palms, California. The first location outside of the Los Angeles metropolitan area opened in San Diego County in 1990, the 57th location in the chain. In 1992, In-N-Out opened its first non-Southern California restaurant, in Las Vegas, Nevada. Its first Northern California location opened the following year in Modesto. Expansion then spread to Northern California, including the San Francisco Bay Area, while additional Las Vegas-area restaurants were added. After opening the 93rd In-N-Out store in Fresno, California, on December 15, 1993, Rich Snyder and four other passengers died in a plane crash on approach to John Wayne Airport in Orange County, California. Upon Rich Snyder's death, Guy Snyder assumed the presidency in January 1994 and continued the company's aggressive expansion until he died from an overdose of painkillers in 1999. Under his leadership, In-N-Out's 100th location was opened in Gilroy, California, on November 10, 1994. He was president for nearly six years, expanding In-N-Out from 93 to 140 locations. His mother Esther subsequently took over the presidency.
Sources: en.wikipedia.org
==== 1998 congressional campaign ==== In 1998, Yates opted to forgo reelection, and Pritzker ran in the Democratic primary to succeed him, reconstituting his campaign committee in April 1997. Also running in the primary were state representative Jan Schakowsky and state senator Howard W. Carroll. The district covered the northern lakefront of Chicago, as well as the suburbs of Evanston and Skokie. It had a large Jewish electorate and had long been regarded as the "Jewish seat" in Illinois's congressional delegation. Yates was Jewish, as were all three Democratic contenders to succeed him. The district had been described as being among the most liberal in the country. Journalist James Ylisela Jr. observed that Pritzker, Schakowsky, and Carroll largely all ran on platforms aligned with the "liberal Democratic Party agenda" that Yates had championed. But the Chicago Tribune wrote that Pritzker and Carroll ran on more moderate platforms than Schakowsky, and therefore potentially wound up competing with each other for many of the same voters. At the time, the election was one of the most expensive congressional primaries in U.S. history, and Pritzker spent nearly $1 million of his own money on his campaign. This included $500,000 on television ads in the Chicago market. He finished third among five candidates in the Democratic primary, with 20.5% of the vote to Schakowsky's 45.1% and Carroll's 34.4%. Schakowsky went on to represent the district for 28 years, retiring after the 2026 election.
The 1–508 PIR served in Regional Command-South. Working mostly out of Kandahar province as the theater tactical force, they mentored the Afghan National Security Force (ANSF), conducting combined operations with both ANSF and NATO partners in the Helmand Province. Supporting the division were the 36th Engineer Brigade, and the 43d Area Support Group.
==== Underinvestment ==== Underinvestment is cited as contributing to a dangerous environment. In attempts to reduce expenses, $1.25 million worth of cuts were placed upon the plant, which affected the factory's employees and their conditions. Kurzman argues that "cuts ... meant less stringent quality control and thus looser safety rules. A pipe leaked? Don't replace it, employees said they were told ... MIC workers needed more training? They could do with less. Promotions were halted, seriously affecting employee morale and driving some of the most skilled ... elsewhere". Workers were forced to use English manuals, even though only a few had a grasp of the language. Subsequent research highlights a gradual deterioration of safety practices in regard to the MIC, which had become less relevant to plant operations. By 1984, only six of the original 12 operators were still working with MIC and the number of supervisory personnel had also been halved. No maintenance supervisor was placed on the night shift and instrument readings were taken every two hours, rather than the previous and required one-hour readings. Workers made complaints about the cuts through their union but were ignored. One employee was fired after going on a 15-day hunger strike. Seventy percent of the plant's employees were fined before the disaster for refusing to deviate from the proper safety regulations under pressure from the management.
Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete. In 2009, an article in Europace journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter defibrillators (ICD).
Isotopes are distinct nuclear species (or nuclides) of the same chemical element. They have the same atomic number (number of protons in their nuclei) and position in the periodic table (and hence belong to the same chemical element), but different nucleon numbers (mass numbers) due to different numbers of neutrons in their nuclei. While all isotopes of a given element have virtually the same chemical properties, they have different atomic masses and physical properties. The term isotope comes from the Greek roots isos (ἴσος "equal") and topos (τόπος "place"), meaning "the same place": different isotopes of an element occupy the same place on the periodic table. It was coined by Scottish doctor and writer Margaret Todd in a 1913 suggestion to the British chemist Frederick Soddy, who popularized the term. The number of protons within the atom's nucleus is called its atomic number and is equal to the number of electrons in the neutral (non-ionized) atom. Each atomic number identifies a specific element, but not the isotope; an atom of a given element may have a wide range in its number of neutrons. The number of nucleons (both protons and neutrons) in the nucleus is the atom's mass number, and each isotope of a given element has a different mass number. For example, carbon-12, carbon-13, and carbon-14 are three isotopes of the element carbon with atomic mass numbers 12, 13, and 14, respectively. The atomic number of carbon is 6, which means that every carbon atom has 6 protons so that the neutron numbers of these isotopes are 6, 7, and 8 respectively.
Sources: en.wikipedia.org
== Research == Chlorpromazine has tentative benefit in animals infected with Naegleria fowleri and shows antifungal and antibacterial activity in vitro. Like other phenothiazine derivatives such as perphenazine, trifluoperazine, and triflupromazine, it inhibits tubulin polymerization.
Some research has shown that sea ice diatoms can use an ancient bacterial metabolic pathway known as the Entner−Doudoroff pathway (EDP) to maintain metabolism and energy production during light limitation. The ability of diatoms to use light for energy also depends on air temperature. As it gets colder, the thylakoid membranes within the microalgae plastids can become dense and compact, which influences how certain photosynthetic proteins (such as the proteins necessary for Photosystems I & II) function and self-assemble. Sea ice diatoms can alter the saturation of the fatty acids that compose the thylakoid membranes as temperatures decrease, which can provide more fluidity to these membranes and result in proper folding of photosynthetic proteins at subzero temperatures. As temperatures within brine pockets decrease, organisms that survive within brine pockets produce substances that can help prevent freezing. Some sea ice diatoms can produce specialized ice-binding proteins and extracellular polymeric substances, which can help increase the habitat space available within a brine pocket by preventing ice formation and reducing the freezing temperature of the brine. Decreased temperatures can also reduce the efficiency of important physiological processes within many microorganisms. Psychrophilic diatoms and bacteria have the ability to regulate their production of proteins, DNA, and enzymes required for metabolism to help maintain metabolic efficiency in colder temperatures.
4 11H + 2 e− → 42He + 2 e+ + 2 e− + 2 νe + 3 γ + 24.7 MeV → 42He + 2 νe + 7 γ + 26.7 MeV The positrons will almost instantly annihilate with electrons, releasing energy in the form of gamma rays. The neutrinos escape from the star carrying away some energy. One nucleus goes on to become carbon, nitrogen, and oxygen isotopes through a number of transformations in a repeating cycle.
Dihexa (developmental code PNB-0408; also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. According to a patent, "Short duration safety studies with dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction, since c-Met is recognized as an oncogene. This is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation."
This influx of sodium ions, in the right conditions, can cause a depolarization event across the membrane. This opens calcium channels, causing intracellular calcium levels to increase. This increase in the concentration of calcium in the cytosol activates ryanodine receptors on the endoplasmic reticulum which causes the release of more calcium into the cytosol. This increase in calcium causes the secretion of somatostatin by the delta cells. Somatostatin inhibits glucagon secretion through the activation of SSTR2, a membrane bound protein that when activated causes a hyperpolarization of the membrane. This hyperpolarization causes voltage gated calcium channels to close, leading to a decrease in intracellular calcium levels. This causes a decrease in exocytosis. In the case of alpha cells, this causes a decrease in the secretion of glucagon. Serotonin inhibits the secretion of glucagon through its receptors on the plasma membrane of alpha cells. Alpha cells have 5-HT1f receptors which are triggered by the binding of serotonin. Once activated, these receptors suppress the action of adenylyl cyclase, which suppresses the production of cAMP. The inhibition of the production of cAMP in turn suppresses the secretion of glucagon. Serotonin is considered a paracrine signal due to the close proximity of beta cells to alpha cells. Glucose can also have a somewhat direct influence on glucagon secretion as well. This is through the influence of ATP. Cellular concentrations of ATP directly reflects the concentration of glucose in the blood.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.